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BACKGROUND
The efficacy of ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleu-
kin-23, as induction and maintenance therapy in patients with ulcerative colitis is unknown.
METHODS
We evaluated ustekinumab as 8-week induction therapy and 44-week maintenance therapy 
in patients with moderate-to-severe ulcerative colitis. A total of 961 patients were ran-
domly assigned to receive an intravenous induction dose of ustekinumab (either 130 mg 
[320 patients] or a weight-range–based dose that approximated 6 mg per kilogram of body 
weight [322]) or placebo (319). Patients who had a response to induction therapy 8 weeks 
after administration of intravenous ustekinumab were randomly assigned again to receive 
subcutaneous maintenance injections of 90 mg of ustekinumab (either every 12 weeks [172 
patients] or every 8 weeks [176]) or placebo (175). The primary end point in the induction 
trial (week 8) and the maintenance trial (week 44) was clinical remission (defined as a total 
score of ≤2 on the Mayo scale [range, 0 to 12, with higher scores indicating more severe 
disease] and no subscore >1 [range, 0 to 3] on any of the four Mayo scale components).
RESULTS
The percentage of patients who had clinical remission at week 8 among patients who re-
ceived intravenous ustekinumab at a dose of 130 mg (15.6%) or 6 mg per kilogram (15.5%) 
was significantly higher than that among patients who received placebo (5.3%) (P<0.001 for 
both comparisons). Among patients who had a response to induction therapy with 
ustekinumab and underwent a second randomization, the percentage of patients who had 
clinical remission at week 44 was significantly higher among patients assigned to 90 mg 
of subcutaneous ustekinumab every 12 weeks (38.4%) or every 8 weeks (43.8%) than among 
those assigned to placebo (24.0%) (P = 0.002 and P<0.001, respectively). The incidence of 
serious adverse events with ustekinumab was similar to that with placebo. Through 52 
weeks of exposure, there were two deaths (one each from acute respiratory distress syn-
drome and hemorrhage from esophageal varices) and seven cases of cancer (one each of 
prostate, colon, renal papillary, and rectal cancer and three nonmelanoma skin cancers) 
among 825 patients who received ustekinumab and no deaths and one case of cancer 
(testicular cancer) among 319 patients who received placebo.
CONCLUSIONS
Ustekinumab was more effective than placebo for inducing and maintaining remission in 
patients with moderate-to-severe ulcerative colitis. (Funded by Janssen Research and Devel-
opment; UNIFI ClinicalTrials.gov number, NCT02407236.)
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Ulcerative colitis is a chronic in-f lammatory disease of the large intes-tine.1,2 Current therapies are limited by 
increased risks of infection3-6 or cancer7 or by loss 
of clinical benefit.8
Ustekinumab (Stelara, Janssen Biotech) is a 
monoclonal antibody to the p40 subunit of inter-
leukin-12 and interleukin-23 and has been ap-
proved for the treatment of psoriasis, psoriatic 
arthritis, and Crohn’s disease.9 In a phase 3 
program for the treatment of Crohn’s disease, 
ustekinumab induced a response at 8 weeks and 
maintained clinical benefit through 52 weeks of 
treatment in patients who had had treatment 
failure with or unacceptable side effects from 
corticosteroids, immunomodulators, or tumor ne-
crosis factor (TNF) antagonists.10 We conducted 
a phase 3 trial (UNIFI) of ustekinumab that in-
volved patients with moderate-to-severe ulcera-
tive colitis, using doses identical to those in the 
phase 3 program involving patients with Crohn’s 
disease.
Me thods
Trial Design and Oversight
The UNIFI trial included an 8-week randomized 
induction trial and a 44-week randomized-with-
drawal maintenance trial (representing 52 weeks 
of treatment). Both were double-blind, placebo-
controlled trials conducted from August 2015 
through August 2018 under one protocol at 244 
sites worldwide. Institutional review boards ap-
proved the protocol (available with the full text 
of this article at NEJM.org); all patients provided 
written informed consent. A steering committee 
of academic investigators and Janssen scientists 
designed the trials, analyzed and interpreted the 
data, and contributed to the manuscript. The first 
author wrote the first draft of the manuscript; 
all authors vouch for the veracity and complete-
ness of the data and for the fidelity of the trials 
to the protocol. Editorial support was provided 
by Janssen.
Patients
Adult patients (≥18 years of age) were eligible if 
they had received a diagnosis of ulcerative colitis 
at least 3 months before screening and had 
moderate-to-severe ulcerative colitis, defined as 
a total score of 6 to 12 on the Mayo scale (range, 
0 to 12, with higher scores indicating more se-
vere disease) and a subscore of 2 or 3 on the 
endoscopic component of the Mayo scale, as 
determined during central review of videoen-
doscopy.11,12 Subscores on each of the four com-
ponents of the Mayo scale range from 0 to 3. 
Eligible patients were required to have had an 
inadequate response to or unacceptable side effects 
from TNF antagonists, vedolizumab, or conven-
tional (i.e., nonbiologic) therapy. (For definitions 
and for more details on the patients, randomiza-
tion, assessments, and end points, see the Sup-
plementary Appendix, available at NEJM.org.)
Stable doses of aminosalicylates and immuno-
modulators were maintained from baseline of 
induction therapy through week 44 of mainte-
nance therapy. Oral corticosteroids were main-
tained at a stable dose during the induction trial 
and tapered when patients entered the mainte-
nance trial.
Previous treatment with interleukin-12 or inter-
leukin-23 antagonists was prohibited. Previous 
TNF antagonist therapy was discontinued at least 
8 weeks before trial entry, and vedolizumab was 
discontinued at least 4 months before trial entry; 
other conventional therapies were discontinued 
at least 2 to 4 weeks before trial entry. Among the 
exclusion criteria were imminent colectomy, gas-
trointestinal conditions that would result in sur-
gery or confound disease-activity assessment, can-
cer, and active infections (including tuberculosis).
Randomization
At week 0 in the induction trial, patients were 
randomly assigned, in a 1:1:1 ratio, to receive a 
single intravenous infusion of 130 mg of ustekinu-
mab, a weight-range–based dose that approxi-
mated 6 mg of ustekinumab per kilogram of 
body weight, or placebo. Randomization was 
performed with the use of permuted blocks, with 
stratification according to status with respect to 
previous treatment failure with biologic agents 
(yes or no) and geographic region (eastern Eu-
rope, Asia, or rest of world).
Patients who had a clinical response to intra-
venous ustekinumab at week 8 (defined as a 
decrease in the total Mayo score of ≥30% and of 
≥3 points from baseline, with an accompanying 
decrease of ≥1 point on the rectal bleeding com-
ponent of the Mayo scale or a rectal bleeding 
subscore of 0 or 1) entered the maintenance 
trial, as did those who did not have a response 
to intravenous placebo and who then received an 
The New England Journal of Medicine 
Downloaded from nejm.org on November 30, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;13 nejm.org September 26, 2019 1203
Ustekinumab for Ulcer ative Colitis
induction dose of intravenous ustekinumab (6 mg 
per kilogram) at week 8 and had a response at 
week 16. At week 0 in the maintenance trial, 
patients were randomly assigned, in a 1:1:1 ratio, 
to receive subcutaneous injections of 90 mg of 
ustekinumab every 12 weeks, 90 mg of ustekinu-
mab every 8 weeks, or placebo through week 40 
(Fig. 1). Randomization was performed with the 
use of permuted blocks, with stratification accord-
ing to intravenous induction treatment (130 mg 
of ustekinumab, 6 mg of ustekinumab per kilo-
gram, or placebo followed by 6 mg of ustekinu-
mab per kilogram), status with respect to clinical 
remission (yes or no) at baseline in the mainte-
nance trial, and oral corticosteroid use (yes or no). 
These patients comprised the randomized main-
tenance population (primary analysis population).
Patients who did not have a response to intra-
venous ustekinumab at week 8 received 90 mg of 
subcutaneous ustekinumab in a blinded manner 
and were reevaluated at week 16; those who had 
a response entered the maintenance trial and 
received 90 mg of subcutaneous ustekinumab 
every 8 weeks (i.e., patients with a delayed re-
sponse to ustekinumab). Patients who had a re-
sponse to intravenous placebo at week 8 received 
subcutaneous placebo; these patients and those 
who had a delayed response to ustekinumab com-
prised the nonrandomized maintenance popula-
tion (Fig. 1).
During maintenance therapy, patients were 
monitored for clinical f lares. Endoscopy was 
performed to confirm loss of response. (Details 
on clinical flares are provided in the Supplemen-
tary Appendix.)
Assessments and End Points
The total Mayo score11,12 and the score on the In-
flammatory Bowel Disease Questionnaire (IBDQ, 
with scores ranging from 32 to 224 and higher 
scores indicating better quality of life)13 were as-
sessed at weeks 0, 8, and 16 (in patients who did 
not have a response to induction therapy at week 8) 
in the induction trial and at week 20 (IBDQ score 
only) and week 44 in the maintenance trial. The 
partial Mayo score (i.e., the total Mayo score 
excluding the endoscopic subscore, with scores 
ranging from 0 to 9 and higher scores indicating 
more severe disease) was evaluated at weeks 2 and 
4 during induction and every 4 weeks during 
maintenance. Concentrations of fecal biomarkers 
(calprotectin and lactoferrin) and serum C-reac-
tive protein (CRP) were evaluated at all visits dur-
ing induction and at weeks 8, 24, and 44 during 
maintenance. Mucosal biopsy samples that were 
obtained from patients who underwent endos-
copy at week 8 during induction and at week 44 
during maintenance were assessed for histologic 
improvement.
The primary end point in the induction trial 
was clinical remission (defined as a total Mayo 
score of ≤2 and no subscore >1) at week 8. Major 
secondary end points at week 8 were endoscopic 
improvement (defined as a Mayo endoscopic sub-
score of 0 or 1), clinical response, and change 
from baseline in the IBDQ score. The IBDQ 
score was a major secondary end point included 
in the protocol but was not included as a pre-
specified major secondary end point in the sta-
tistical analysis plan submitted to the Food and 
Drug Administration (FDA). Histo-endoscopic 
mucosal healing (which required both histologic 
improvement [defined as neutrophil infiltration 
in <5% of crypts, no crypt destruction, and no 
erosions, ulcerations, or granulation tissue]14,15 
and endoscopic improvement) was an additional 
end point that was controlled for multiple com-
parisons at week 8. In the maintenance trial, the 
primary end point was clinical remission at week 
44; major secondary end points were mainte-
nance of clinical response through week 44, 
endoscopic improvement at week 44, corticoste-
roid-free clinical remission at week 44, and 
maintenance of clinical remission through week 
44 among patients in clinical remission at base-
line in the maintenance trial.
An alternative primary end point of clinical 
remission that excluded the subscore on the phy-
sician’s global assessment component of the 
Mayo scale was also prespecified to support the 
FDA submission. This definition required an ab-
solute stool number of 3 or fewer (average daily 
stool number during 3 days before a visit), a Mayo 
rectal bleeding subscore of 0, and a Mayo endo-
scopic subscore of 0 or 1.
Histologic improvement, histo-endoscopic mu-
cosal healing, and changes in the partial Mayo 
score, IBDQ score, serum CRP concentration, 
and concentrations of fecal biomarkers were as-
sessed separately in the induction and mainte-
nance trials. Safety follow-up assessment (con-
comitant medications, adverse events, serious 
adverse events, and ulcerative colitis–related hos-
pitalizations and surgical procedures) occurred 
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during the induction trial through week 8 or 
week 16 when patients entered the maintenance 
trial or 20 weeks after the final induction dose 
for those discontinuing the trial and during the 
maintenance trial through week 44 (i.e., 52 weeks 
of treatment).
Pharmacokinetics and Immunogenicity
Serum ustekinumab concentrations were evaluated 
at all visits during induction and every 4 weeks 
during maintenance. Antidrug antibodies were 
evaluated by means of a drug-tolerant electro-
chemiluminescence assay at weeks 0, 4, 8, and 
16 (in patients who did not have a response to 
induction therapy at week 8) during induction 
and at weeks 4, 12, 24, 36, and 44 during main-
tenance. The relationship between exposure and 
response was assessed on the basis of quartiles 
of serum ustekinumab concentration at week 8 
during induction (for efficacy end points in the 
induction trial) and at week 24 during mainte-
nance (for efficacy end points in the maintenance 
trial).
Statistical Analysis
The primary and major secondary end points in 
the induction trial (including histo-endoscopic 
mucosal healing) and the maintenance trial were 
controlled for multiple comparisons. The type I 
error rate in each trial was controlled at an alpha 
level of 0.05 over the end points that were con-
trolled for multiple comparisons with the use of 
a prespecified multiple-testing procedure. A dif-
ferent prespecified multiple-testing procedure 
was used to support the FDA submission. (For 
details on multiple-testing procedures and pre-
specified subgroups, see the Supplementary Ap-
pendix.)
Dichotomous end points were compared be-
tween each ustekinumab group and the placebo 
group with the use of a two-sided, Cochran–
Mantel–Haenszel chi-square test with adjustment 
for stratification variables. Continuous end points 
were analyzed by means of analysis of covariance 
or analysis of covariance on van der Waerden 
normal scores with adjustment for baseline value 
and stratification variables.
Analyses of other end points were not ad-
justed for multiple comparisons, and results are 
reported with 95% confidence intervals not ad-
justed for multiple comparisons, without P values; 
inferences drawn from these results may not be 
reproducible. (See Tables S1A and S1B in the Sup-
plementary Appendix and the statistical analysis 
plan within the protocol, available at NEJM.org.)
Unless otherwise specified, all efficacy analy-
ses were based on the intention-to-treat princi-
ple. Data sets for the primary efficacy analyses 
comprise the patients who underwent random-
ization in the induction trial or maintenance trial. 
Prespecified efficacy analyses were also conduct-
ed for patients who entered the maintenance trial 
after having a delayed response to ustekinumab. 
To evaluate the consistency of the treatment ef-
fect for the primary end point, clinical remission 
was analyzed in prespecified subgroups.
Patients were considered not to have reached 
dichotomous end points if they had a prohibited 
change in concomitant medication for ulcerative 
colitis, had undergone an ostomy or colectomy 
before week 8 (during induction) or week 44 
(during maintenance), had used a rescue medica-
Figure 1 (facing page). Overall Trial Flow.
In the induction trial, status with respect to response 
or nonresponse was determined by means of an inter‑
active Web response system and by the subscore on the 
endoscopic component of the Mayo scale as assessed 
by the local endoscopist. The patients who had a re‑
sponse to intravenous ustekinumab (UST) at week 8, 
as well as those who did not have a response to intra‑
venous placebo and who then received an induction 
dose of intravenous ustekinumab (6 mg per kilogram 
of body weight) at week 8 and had a response at week 
16, made up the randomized primary analysis popula‑
tion in the maintenance trial. One patient who had a 
response to intravenous ustekinumab (6 mg per kilo‑
gram) at week 8 and three patients who had a response 
to intravenous placebo did not enter the maintenance 
trial. Patients who had a delayed response to induction 
therapy with ustekinumab (i.e., those who did not have 
a response to intravenous ustekinumab and who then 
received ustekinumab subcutaneously at week 8 and 
had a response at week 16) entered the maintenance 
trial but did not undergo randomization. Patients who 
had a response to intravenous placebo in the induction 
trial entered the maintenance trial but did not undergo 
randomization. Baseline (week 0) in the maintenance 
trial is the same as week 8 or week 16 in the induction 
trial, depending on when patients entered maintenance 
(week 8 or week 16). Patients who had a response to 
intravenous ustekinumab at week 8 in the induction 
trial and then completed the maintenance trial through 
week 44 had 52 weeks of overall exposure; patients 
who had a response to ustekinumab at week 16 in the 
induction trial could have up to 60 weeks of overall ex‑
posure. SFU denotes safety follow‑up (lasting 20 weeks 
after the last dose of ustekinumab or placebo).
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tion after a clinical flare (during maintenance), 
or had discontinued ustekinumab or placebo 
owing to lack of efficacy or an adverse event of 
worsening disease during maintenance. For con-
tinuous end points, patients who had a treat-
ment failure had their value at baseline in the 
induction trial carried forward from the time 
of the event onward (i.e., consistent with non-
response for dichotomous end points).
For dichotomous end points, including all end 
points that were controlled for multiple com-
parisons, patients with missing data were con-
sidered not to have reached the end points. Pre-
specified sensitivity analyses including methods 
to account for missing data were conducted to 
test the robustness of the primary end point 
analyses for both definitions of clinical remis-
sion. (For more information on the handling of 
missing data, see the Supplementary Appendix.)
Assuming an incidence of clinical remission 
of 7% in the placebo group and 19% in each 
ustekinumab group, we calculated that 317 pa-
tients per induction group would provide more 
than 90% power for the primary end point at 
week 8 using a step-up Hochberg testing proce-
dure at a two-sided alpha level of 0.05. This 
sample size would also provide enough patients 
for the primary population of the maintenance 
trial. Assuming an incidence of clinical remis-
sion of 20% in the group receiving placebo and 
40% in the group receiving 90 mg of subcuta-
neous ustekinumab every 8 weeks, 109 patients 
per maintenance group would provide 90% 
power for the primary end point at week 44 at 
a two-sided significance level of 0.05 on the 
basis of the fixed-sequence testing procedure, 
starting with the high-dose ustekinumab group 
(every 8 weeks).
In the safety analyses, data for patients who 
received at least one dose of ustekinumab or 
placebo in the induction trial were analyzed 
according to the substance received, and data 
for patients who received at least one dose of 
ustekinumab or placebo in the maintenance 
trial were analyzed according to the assigned 
trial group. The frequency and types of adverse 
events were summarized. Immunogenicity analy-
ses included patients who had at least one 




Of 961 patients who underwent randomization, 
912 (94.9%) completed the induction trial: 783 
(81.5%) who entered the maintenance trial and 
129 (13.4%) who did not enter the maintenance 
trial completed the final safety visit. In the main-
tenance trial, 523 patients underwent random-
ization (primary population) and 260 did not. 
Most patients (494 of 523, 94.5%) who under-
went randomization in the maintenance trial 
completed the trial. (See Fig. S1A through S1C in 
the Supplementary Appendix.)
At baseline in the induction trial, patients 
were randomly assigned to receive a single intra-
venous infusion of placebo (319 patients), ustekinu-
mab at a dose of 130 mg (320), or ustekinumab at 
a dose approximating 6 mg per kilogram (322). 
Patient characteristics were generally similar 
across trial groups in the induction and mainte-
nance trials (Table 1, and Table S2 in the Supple-
mentary Appendix).
Among 51.1% of randomly assigned patients 
who had previous treatment failure with bio-
logic agents (491 of 961), a total of 98.8% (485 
of 491) had had treatment failure with at least 
one TNF antagonist, 32.6% (160 of 491) had had 
treatment failure with both a TNF antagonist 
and vedolizumab, and 1.2% (6 of 491) had had 
treatment failure with vedolizumab only. Among 
patients who did not have previous treatment 
failure with biologics, 94.3% (443 of 470) had 
not received biologics and 5.7% (27 of 470) had 
received biologics but did not have documented 
treatment failure (Table 1; also see the Supple-
mentary Appendix).
Induction Therapy
At week 8, the percentages of patients in clinical 
remission were higher in the groups that re-
ceived ustekinumab at a dose of either 130 mg 
(15.6% [50 of 320 patients]) or 6 mg per kilo-
gram (15.5% [50 of 322]) than in the placebo 
group (5.3% [17 of 319]) (P<0.001 for both com-
parisons with placebo) (Fig. 2). The results were 
similar for the alternative primary end point of 
clinical remission that excluded the subscore on 
the physician’s global assessment component of 
the Mayo scale: 16.6% (53 of 320 patients) and 
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Male sex — no. (%) 197 (61.8) 190 (59.4) 195 (60.6)
Age — yr 41.2±13.5 42.2±13.9 41.7±13.7
Weight — kg 72.9±16.8 73.7±16.8 73.0±19.3
Duration of disease — yr 8.0±7.2 8.1±7.2 8.2±7.8
Total Mayo score‡ 8.9±1.6 8.9±1.6 8.9±1.5
Score of 6–10, indicating moderate disease  
— no./total no. (%)
263/319 (82.4) 271/320 (84.7) 276/321 (86.0)
Disease limited to left side of colon — no./total no. (%) 167/316 (52.8) 183/318 (57.5) 168/320 (52.5)
C‑reactive protein — mg/liter§
Median 4.7 4.5 4.8
IQR 1.4–10.0 1.6–9.9 1.8–13.7
Fecal calprotectin — mg/kg¶
Median 1224.0 1382.0 1506.5
IQR 496.0–2224.0 564.5–2681.0 621.5–3192.5
Medications for ulcerative colitis taken at baseline
≥1 Medication — no. (%) 283 (88.7) 290 (90.6) 294 (91.3)
Aminosalicylates — no. (%) 207 (64.9) 215 (67.2) 238 (73.9)
Corticosteroids — no. (%)‖ 157 (49.2) 173 (54.1) 168 (52.2)
Median dose (IQR) — mg/day 20.0 (10.0–20.0) 20.0 (10.0–20.0) 20.0 (10.0–20.0)
Immunomodulator — no. (%)** 89 (27.9) 93 (29.1) 89 (27.6)
No history of disease refractory to treatment with biologic 
agents — no. (%)
158 (49.5) 156 (48.8) 156 (48.4)
Had not received biologics 151 (47.3) 145 (45.3) 147 (45.7)
Had received biologics but did not have documented 
treatment failure
7 (2.2) 11 (3.4) 9 (2.8)
History of treatment failure with biologics — no. (%)†† 161 (50.5) 164 (51.2) 166 (51.6)
Only TNF antagonist 112 (35.1) 107 (33.4) 106 (32.9)
Vedolizumab 49 (15.4) 57 (17.8) 60 (18.6)
≥1 TNF antagonist, regardless of vedolizumab 159 (49.8) 162 (50.6) 164 (50.9)
Any TNF antagonist and vedolizumab 47 (14.7) 55 (17.2) 58 (18.0)
*  Plus–minus values are means ±SD. IQR denotes interquartile range, and TNF tumor necrosis factor.
†  Weight‑range–based doses of ustekinumab approximate 6 mg per kilogram of body weight (with 260 mg prescribed 
for patients weighing ≤55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing  
>85 kg).
‡  Total scores on the Mayo scale range from 0 to 12, with higher scores indicating more severe disease.
§  Data for C‑reactive protein concentrations were available for 951 patients: 316 receiving placebo, 315 receiving 130 mg 
of ustekinumab, and 320 receiving 6 mg of ustekinumab per kilogram.
¶  Data for fecal calprotectin concentrations were available for 855 patients: 289 receiving placebo, 296 receiving 130 mg 
of ustekinumab, and 300 receiving 6 mg of ustekinumab per kilogram.
‖  Corticosteroids included budesonide and beclomethasone dipropionate. Shown is the prednisone‑equivalent dose. 
Data on corticosteroid dose were available for 418 patients: 133 receiving placebo, 143 receiving 130 mg of ustekinumab, 
and 142 receiving 6 mg of ustekinumab per kilogram.
**  Immunomodulators included azathioprine, mercaptopurine, and methotrexate.
††  Patients may have reported more than one reason for treatment failure with a TNF antagonist.
Table 1. Demographic and Clinical Characteristics at Baseline in the Induction Trial (Randomly Assigned Patients).*
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18.9% (61 of 322) in the respective ustekinumab 
groups and 6.3% (20 of 319) in the placebo 
group (P<0.001 for both comparisons with pla-
cebo) (Fig. S2 in the Supplementary Appendix).
The efficacy observed in prespecified sub-
groups for both ustekinumab groups was con-
sistent with that in the overall trial population. 
Results of analyses according to treatments 
received before the trial suggest benefits of 
ustekinumab across subgroups. For both defini-
tions of clinical remission, the results of sensi-
tivity analyses were consistent. (For details, see 
Fig. S3A through S3H and Tables S4 and S5 in 
the Supplementary Appendix.)
The percentages of patients who met major 
secondary end points or had histo-endoscopic 
mucosal healing were significantly higher in 
both ustekinumab groups than in the placebo 
group (Fig. 2). Through week 8, the median 
changes from baseline in the IBDQ score were 
significantly greater in both ustekinumab groups 
than in the placebo group. The percentage of 
patients who had histologic improvement at 
week 8 was higher in both ustekinumab groups 
than in the placebo group. Improvements from 
baseline that were observed in the partial Mayo 
scores and in concentrations of fecal calprotec-
tin and lactoferrin and serum CRP support the 
clinical outcomes. (See Tables S6 through S11 in 
the Supplementary Appendix.)
Among patients who did not have a clinical 
response to intravenous ustekinumab and who 
received 90 mg of subcutaneous ustekinumab at 
week 8, a total of 59.7% (139 of 233) had a de-
layed clinical response at week 16. Among all 
patients in the induction trial who were initially 
assigned to ustekinumab, 77.6% (498 of 642) 
had a clinical response within 16 weeks. In ad-
dition, among patients who did not have a clini-
cal response to intravenous placebo and who 
then received intravenous ustekinumab at a dose 
of 6 mg per kilogram, 67.9% (125 of 184) had a 
clinical response at week 16.
Maintenance Therapy
Among patients who had a clinical response to 
induction treatment with ustekinumab, the per-
centages of patients who had clinical remission 
at week 44 (52 weeks after intravenous induc-
tion) were significantly higher in the groups that 
received 90 mg of ustekinumab every 12 weeks 
(38.4% [66 of 172 patients]) or every 8 weeks 
(43.8% [77 of 176]) than in the placebo group 
(24.0% [42 of 175]) (P = 0.002 and P<0.001, re-
spectively, for the comparison with placebo) 
(Fig. 3). The results were similar for the alterna-
tive definition of clinical remission: 39.5% (68 of 
172 patients) and 42.6% (75 of 176) in the re-
spective ustekinumab groups and 24.6% (43 of 
175) in the placebo group (P = 0.002 and P<0.001, 
respectively, for the comparison with placebo). 
Efficacy among prespecified subgroups was con-
Figure 2. Patients with Clinical Remission, Endoscopic Improvement, 
 Clinical Response, or Histo-Endoscopic Mucosal Healing at Week 8  
in the Induction Trial.
Weight‑range–based doses of ustekinumab approximating 6 mg per kilo‑
gram were as follows: 260 mg (weight, ≤55 kg), 390 mg (weight, >55 kg 
and ≤85 kg), and 520 mg (weight, >85 kg). Patients who had a prohibited 
change in concomitant medication for ulcerative colitis or who had under‑
gone an ostomy or colectomy before week 8 were considered not to have 
met the end point. Clinical remission was defined as a total score of 2 or 
less on the Mayo scale (range, 0 to 12, with higher scores indicating more 
severe disease) and no subscore greater than 1 (range, 0 to 3) on any of  
the four Mayo scale components. Endoscopic improvement was defined  
as a Mayo endoscopic subscore of 0 or 1. Clinical response was defined as 
a decrease in the total Mayo score of at least 30% and of at least 3 points 
from baseline, with an accompanying decrease of at least 1 point on the 
Mayo rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. Histo‑
endoscopic mucosal healing required both histologic improvement (defined 
as neutrophil infiltration in <5% of crypts, no crypt destruction, and no 
erosions, ulcerations, or granulation tissue) and endoscopic improvement. 
Patients with missing data on all four Mayo subscores at week 8 were con‑
sidered not to be in clinical remission or not to have a clinical response at 
week 8. Patients who had a missing Mayo endoscopic subscore at week 8 
were considered not to have endoscopic improvement. Patients who were 
missing any Geboes score components pertaining to histologic improve‑
ment at week 8 were considered not to have histologic improvement. The 
analyses for histologic improvement and histo‑endoscopic mucosal healing 
excluded data from patients whose status with respect to these end points 
could not be determined at week 8 owing to a biopsy sample that could not 
be evaluated (i.e., a biopsy sample was obtained but could not be assessed 
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sistent with that in the overall randomized popu-
lation. For both definitions of clinical remission, 
the results of sensitivity analyses were consis-
tent. (See Figs. S4 and S5A through S5L and 
Table S5 in the Supplementary Appendix.)
The percentages of patients with maintenance 
of clinical response through week 44, endoscopic 
improvement at week 44, or corticosteroid-free 
clinical remission (with either definition of clini-
cal remission) at week 44 were significantly 
higher in both ustekinumab groups than in the 
placebo group (Fig. 3). Among patients in clini-
cal remission at baseline in the maintenance 
trial, the percentage who had maintenance of 
clinical remission through week 44 was not sig-
nificantly higher among those receiving 90 mg 
of ustekinumab every 8 weeks than among those 
receiving placebo; when the alternative definition 
of clinical remission was used, the percentage 
was significantly higher in both ustekinumab 
groups than in the placebo group. Results of 
analyses according to treatments received before 
the trial suggest benefits of ustekinumab across 
subgroups for all end points except maintenance 
of clinical remission. (See Fig. S4 and Table S4 
in the Supplementary Appendix.)
Among patients receiving corticosteroids at 
baseline, the percentages of those who discon-
tinued corticosteroid use at least 90 days before 
week 44 were higher in the groups that received 
90 mg of ustekinumab every 12 weeks (67% [55 
of 82 patients]) or every 8 weeks (77% [71 of 92]) 
than in the placebo group (44% [40 of 91]); 
97.2% of patients in clinical remission at week 
44 (both definitions) (139 of 143) were cortico-
steroid-free at week 44. Corticosteroids were dis-
continued sooner by patients receiving ustekinu-
mab (median, 7 weeks in each group) than by 
those receiving placebo (median, 16 weeks) 
(Table S12 in the Supplementary Appendix).
The percentage of patients who had histo-
logic improvement was higher in both ustekinu-
mab groups than in the placebo group, as was 
the percentage of patients who had histo-endo-
scopic mucosal healing. Through week 44, median 
IBDQ scores were maintained or improved with 
Figure 3. Patients’ Responses to Maintenance Therapy.
Patients who had a clinical response to intravenous ustekinumab during the induction trial were randomly assigned to receive subcuta‑
neous injections of placebo or one of two doses of ustekinumab on entry to the maintenance trial. Patients who had a prohibited change 
in medication for ulcerative colitis, had undergone an ostomy or colectomy, or had used a rescue medication after a clinical flare or who 
had discontinued ustekinumab or placebo owing to lack of therapeutic effect or owing to an adverse event of worsening of ulcerative 
colitis before the week 44 visit were considered not to have met the dichotomous end points or had their value at baseline in the induc‑
tion trial carried forward from the time of the event onward for continuous end points. Patients with missing data on all four Mayo sub‑
scores at week 44 were considered not to have clinical remission, clinical response, or corticosteroid‑free clinical remission at week 44. 
Patients who did not have clinical remission or clinical response at any time before week 44 were considered not to be in clinical remis‑
sion among patients in clinical remission at week 0 in the maintenance trial or not to have maintenance of clinical response through 
week 44. Patients who had a missing value for corticosteroid use at week 44 had their last value carried forward. Patients who had a 
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ustekinumab every 12 weeks and every 8 weeks 
but worsened with placebo. Improvements in 
partial Mayo scores and concentrations of CRP, 
lactoferrin, and calprotectin that were observed 
at baseline in the maintenance trial were main-
tained in both ustekinumab groups, whereas 
results for these measures worsened in the pla-
cebo group. (See Tables S13 through S19 in the 
Supplementary Appendix.)
Among patients who had a delayed response 
to ustekinumab and received 90 mg every 8 weeks, 
62.4% (98 of 157) had maintenance of clinical 
response through week 44. The percentages of 
patients who met this end point or other effi-
cacy measures at week 44 were lower than those 
among patients who had a response to intrave-
nous ustekinumab and were randomly assigned 
to 90 mg of subcutaneous ustekinumab every 
8 weeks during maintenance (see the Supplemen-
tary Appendix).
The percentage of patients who had an ulcer-
ative colitis–related hospitalization was lower in 
both ustekinumab groups than in the placebo 
group through week 8 in the induction trial and 
remained lower through week 44 in the mainte-
nance trial. (Details on ulcerative colitis–related 
hospitalizations and surgical procedures are 
provided in Table S20 in the Supplementary Ap-
pendix.)
Safety
Through the final safety visit in the induction 
trial, the percentages of patients who reported at 
least one adverse event in the groups receiving 
130 mg of ustekinumab, 6 mg of ustekinumab 
per kilogram, and placebo were 41.4%, 50.6%, 
and 48.0%, respectively. The percentages of pa-
tients in these groups with at least one serious 
adverse event were 3.7%, 3.4%, and 6.9%, re-
spectively. Through week 44 in the maintenance 
trial, the percentages of randomly assigned pa-
tients who reported at least one adverse event 
in the groups receiving 90 mg of ustekinumab 
every 12 weeks, 90 mg of ustekinumab every 
8 weeks, and placebo were 69.2%, 77.3%, and 
78.9%, respectively. The percentages of patients 
with at least one serious adverse event were 
7.6%, 8.5%, and 9.7%, respectively; the percent-
ages of patients with a serious infection were 
3.5%, 1.7%, and 2.3%, respectively. Findings in 
the nonrandomized population were consistent 
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and Tables S21 and S22 in the Supplementary 
Appendix).
Adverse events of interest that occurred 
among patients receiving ustekinumab or placebo 
through 52 weeks of treatment are summarized 
below and in the Supplementary Appendix. Two 
deaths before week 44 (sudden death attributed 
to hemorrhage from esophageal varices and 
death from acute respiratory distress syndrome 
[ARDS]) and one death after week 44 (a patient 
with failure to thrive had a cardiac arrest) oc-
curred among patients receiving ustekinumab. 
Cancer occurred in 7 of 825 patients who re-
ceived ustekinumab (1 each of prostate, colon, 
renal papillary, and rectal cancer and 3 non-
melanoma skin cancers) and 1 of 319 patients 
who received placebo (testicular cancer). Four 
patients who received ustekinumab presented with 
potential opportunistic infections: cytomegalo-
virus colitis (in 2 patients during maintenance), 
legionella pneumonia (in 1 patient during induc-
tion), and concurrent ophthalmic and oral herpes 
simplex infections (in 1 patient during mainte-
nance). Three major cardiovascular events oc-
curred: a nonfatal cardiac arrest (in a patient 
who received ustekinumab during induction and 
placebo during maintenance), an acute myocar-
dial infarction (in a patient who received ustekinu-
mab and died of ARDS complications), and a 
nonfatal stroke (in a patient who received pla-
cebo during induction).
Pharmacokinetics and Immunogenicity
Positive associations were observed between se-
rum ustekinumab concentrations at week 8 and 
clinical response at week 8 and between serum 
ustekinumab concentrations at week 24 and clini-
cal remission at week 44. Among 505 patients 
who received ustekinumab during both induction 
and maintenance, antidrug antibodies developed 
in 4.6% (23 of 505). Among the 23 patients, 22% 
(5 of 23) had neutralizing antibodies, and 39% 
(9 of 23) had transient antibodies. (See Figs. S6 
and S7 in the Supplementary Appendix.)
Discussion
In this phase 3 trial of an antagonist of interleu-
kin-12 and interleukin-23 involving patients with 
moderate-to-severe ulcerative colitis, ustekinu-
mab was more effective than placebo in achieving 
induction of clinical remission at 8 weeks. This 
effect was observed in patients with or without 
previous treatment failure with biologic agents, 
including those who had not received biologics. 
Among patients who had a response to induction 
therapy with intravenous ustekinumab and who 
underwent a second randomization, those assigned 
to either regimen of subcutaneous ustekinumab 
were more likely to be in clinical remission at 
44 weeks than those assigned to placebo. For all 
prespecified major secondary end points in the 
induction and maintenance trials, the percent-
ages of patients were significantly higher in the 
ustekinumab groups than in the placebo group, 
except for the major secondary end point of 
maintenance of clinical remission through week 
44 among patients in clinical remission at base-
line. For that end point, the percentage of pa-
tients in the group receiving ustekinumab every 
12 weeks was higher than in the placebo group 
for both remission definitions, but the percent-
age in the group receiving ustekinumab every 
8 weeks was higher than in the placebo group 
only for the alternative definition of clinical re-
mission that was used to support the FDA sub-
mission.
Because this program had a randomized-
withdrawal design, the percentages of patients 
in clinical remission reported at week 44 should 
be interpreted in the context of the trial design. 
Only those patients who had a response to in-
duction therapy with intravenous ustekinumab 
underwent a second randomization in the main-
tenance trial; therefore, the proportion of patients 
who had clinical remission with ustekinumab 
treatment would be different if all patients en-
tered the maintenance trial regardless of the 
clinical outcome in the induction trial.
The therapeutic goal in patients with ulcer-
ative colitis is to induce and maintain long-term 
remission, because the disease often has a relaps-
ing and remitting course.16,17 Endoscopic improve-
ment in mucosal appearance is associated with 
better subsequent long-term outcomes in patients 
with ulcerative colitis.18,19 Histologic improvement 
has also been associated with better long-term 
outcomes, including reductions in corticosteroid 
use and relapse.20,21 The combination of endo-
scopic and histologic improvement has been 
suggested by the research community and regu-
latory bodies21-26 as the most complete method of 
assessing mucosal healing.17
In this trial, we combined macroscopic and 
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microscopic evidence of mucosal improvement 
to define histo-endoscopic mucosal healing. Be-
cause there was no accepted definition of histo-
logic improvement, criteria were developed with 
the use of data from completed prospective 
clinical trials involving patients with ulcerative 
colitis.15 Histo-endoscopic mucosal healing, an 
end point that was controlled for multiple com-
parisons in the induction trial, was induced by 
both intravenous doses of ustekinumab and main-
tained by both subcutaneous doses. The associa-
tion of this end point with long-term clinical 
outcomes and prevention of colon cancer requires 
further exploration.
In analyses of other end points, improvements 
in partial Mayo scores and reductions in serum 
and fecal concentrations of inflammatory bio-
markers that were observed with induction were 
sustained through maintenance. Although our 
findings suggest that ustekinumab was effective 
in patients with or without previous treatment 
failure with biologics for both induction and 
maintenance therapy, the percentages of pa-
tients in whom each end point was achieved 
were lower across groups with previous treat-
ment failure with biologics.
Some possible differences in dose were ob-
served for several end points. At week 8, a higher 
percentage of patients who had a clinical re-
sponse, larger decreases in the partial Mayo 
score, and greater reductions in fecal lactoferrin 
and calprotectin concentrations were observed 
with approximately 6 mg of ustekinumab per 
kilogram than with 130 mg of ustekinumab. At 
week 44, for the more objective and stringent 
end points (e.g., endoscopic improvement, histo-
endoscopic mucosal healing, corticosteroid-free 
remission, and elimination of corticosteroids 
≥90 days before week 44 among patients receiv-
ing corticosteroids at baseline in the maintenance 
trial), greater clinical benefit was observed with 
ustekinumab every 8 weeks than with ustekinu-
mab every 12 weeks.
Cancers developed in seven patients who re-
ceived ustekinumab (including three cases of 
nonmelanoma skin cancer) and in one patient 
who received placebo. Potential opportunistic in-
fections developed in four patients who received 
ustekinumab. There were no cases of anaphy-
laxis or serious hypersensitivity reactions in pa-
tients who received ustekinumab.
In conclusion, in this trial involving patients 
with moderate-to-severe ulcerative colitis despite 
current or previous treatment with conventional 
or biologic therapy, ustekinumab was more effec-
tive than placebo for inducing and maintaining 
remission.
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